Investment analysts at StockNews.com initiated coverage on shares of Trinity Biotech (NASDAQ:TRIB – Get Rating) in a research note issued to investors on Friday. The brokerage set a "buy" rating on the stock.
Separately, TheStreet cut shares of Trinity Biotech from a "c-" rating to a "d" rating in a research report on Tuesday, July 5th.
Get Trinity Biotech alerts:Trinity Biotech Trading Down 5.1 %
Shares of TRIB opened at $1.16 on Friday. The stock has a market capitalization of $31.16 million, a P/E ratio of -2.27 and a beta of 1.33. The firm's fifty day simple moving average is $1.35 and its two-hundred day simple moving average is $1.22. Trinity Biotech has a 12 month low of $0.86 and a 12 month high of $3.05.
Trinity Biotech (NASDAQ:TRIB – Get Rating) last issued its quarterly earnings results on Thursday, June 30th. The company reported ($0.08) EPS for the quarter. The firm had revenue of $18.78 million for the quarter. Trinity Biotech had a negative net margin of 15.10% and a negative return on equity of 347.92%.Hedge Funds Weigh In On Trinity Biotech
Several large investors have recently added to or reduced their stakes in TRIB. Atria Wealth Solutions Inc. bought a new position in Trinity Biotech in the 1st quarter valued at about $27,000. Virtu Financial LLC bought a new position in Trinity Biotech in the 1st quarter valued at about $40,000. Whitefort Capital Management LP bought a new position in Trinity Biotech in the 4th quarter valued at about $50,000. Envestnet Asset Management Inc. bought a new position in Trinity Biotech in the 4th quarter valued at about $159,000. Finally, Highbridge Capital Management LLC purchased a new stake in Trinity Biotech in the 1st quarter valued at about $1,221,000. Institutional investors own 27.11% of the company's stock.
Trinity Biotech Company Profile
(Get Rating)
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Recommended Stories
- Get a free copy of the StockNews.com research report on Trinity Biotech (TRIB)
- Could Nike Stock be Oversold, but Still Overvalued?
- Is Alcoa A Buy After Strong Q2 Results And More Share Buybacks?
- Will Royal Caribbean's Broadband Partnership Drive Revenue?
- Chip Gear Maker Entegris Has Potential, But Is It Buyable Now?
- DocuSign Has Important Issues to Address When it Reports Earnings
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.